While HIF2α has been found to have a clear oncogenic role in ccRCC with a HIF2α inhibitor in the drug development pipeline23–25, evidence for the role of HIF1α in this disease has been conflicting. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.